Covered recipient · General Payments record
SHIRLEY A ICE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,723.76
- Reported across 260 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $321.08 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $117.56 | 5 |
| Teva Pharmaceuticals USA, Inc. | $49.35 | 2 |
| Lilly USA, LLC | $35.57 | 2 |
| Merck Sharp & Dohme Corporation | $22.88 | 1 |
| Astellas Pharma US Inc | $19.05 | 1 |
| DEXCOM, INC. | $18.62 | 1 |
| Acerta Pharma LLC | $15.05 | 1 |
| Amgen Inc. | $14.41 | 1 |
| PFIZER INC. | $14.36 | 1 |
| GlaxoSmithKline, LLC. | $14.23 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.12 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103963603 | CMS |
| ABBVIE INC. | $22.54 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103963605 | CMS |
| ABBVIE INC. | $19.49 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103963607 | CMS |
| ABBVIE INC. | $18.99 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103963609 | CMS |
| ABBVIE INC. | $34.42 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103963611 | CMS |
| Amgen Inc. | $14.41 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117585324 | CMS |
| Astellas Pharma US Inc | $19.05 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139365333 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.05 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105679375 | CMS |
| Dexcom, Inc. | $18.62 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153336441 | CMS |
| GlaxoSmithKline, LLC. | $14.23 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116607124 | CMS |
| Lilly USA, LLC | $15.22 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135377596 | CMS |
| Lilly USA, LLC | $20.35 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135427534 | CMS |
| Merck Sharp & Dohme LLC | $22.88 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141985371 | CMS |
| PFIZER INC. | $14.36 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131877206 | CMS |
| Teva Pharmaceuticals USA, Inc. | $22.87 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151719042 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.48 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151719088 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.